
Australian FY22 earnings preview - CSL
CSL Limited (CSL) is Australia's largest drugmaker, one of the world's largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines.
Share this:
CSL Limited (CSL) is Australia's largest drugmaker, one of the world's largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines.
CSL is the third largest company in the ASX200 with an index weighting of ~6.9% and reports its Full Year numbers this Wednesday the 17th of August.
COVID-19 provided a headwind for CSL's supply chains and the collection of plasma, an essential raw material used to produce many of CSL's therapies, which account for almost half of CSL's sales. In the first 1H 2022, CSL reported a 5% fall in Net Profit After Tax (NPAT) to $1.76bn.
In December 2021, CSL announced it would acquire 100% of Vifor Pharma Ltd, a global speciality pharmaceutical company with leadership in renal disease and iron deficiency. After a delay to do with antitrust issues, the US$11.7bn deal received regulatory clearance and was recently completed.
While the deal will have no bearing on the company’s earnings for 2022 it will provide the company with a bigger footprint within the industry, a more diversified earnings stream and boost CSL’s earnings in 2023.
Along with strong demand for plasma products and a drop in the fees paid to plasma donors (boosted payment incentives no longer needed to attract donors as they were during COVID-19), the company ends this financial year in a strong position.
CSL’s earnings are heavily screwed to the first half of the year. Full Year NPAT is expected to be in the range of $2.15bn-$2.25bn.
CSL Daily Chart
The decline from the $342.75 high of February 2020 to the $240.10 low in February 2022 completed a correction and the CSL share price is eyeing trend channel resistance near $310/12 where profit taking/selling is likely to emerge.
Should the CSL share price break above the resistance at $310/12 and then above resistance at $320/21 it would likely open up a retest and break of the $342.75 high.
Source Tradingview. The figures stated are as of August 15, 2022. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation
How to trade with City Index
You can trade with City Index by following these four easy steps:
- Open an account, or log in if you’re already a customer
• Open an account in the UK
• Open an account in Australia
• Open an account in Singapore
- Search for the company you want to trade in our award-winning platform
- Choose your position and size, and your stop and limit levels
- Place the trade
CSL Limited (CSL) is Australia's largest drugmaker, one of the world's largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines.
CSL is the third largest company in the ASX200 with an index weighting of ~6.9% and reports its Full Year numbers this Wednesday the 17th of August.
COVID-19 provided a headwind for CSL's supply chains and the collection of plasma, an essential raw material used to produce many of CSL's therapies, which account for almost half of CSL's sales. In the first 1H 2022, CSL reported a 5% fall in Net Profit After Tax (NPAT) to $1.76bn.
In December 2021, CSL announced it would acquire 100% of Vifor Pharma Ltd, a global speciality pharmaceutical company with leadership in renal disease and iron deficiency. After a delay to do with antitrust issues, the US$11.7bn deal received regulatory clearance and was recently completed.
While the deal will have no bearing on the company’s earnings for 2022 it will provide the company with a bigger footprint within the industry, a more diversified earnings stream and boost CSL’s earnings in 2023.
Along with strong demand for plasma products and a drop in the fees paid to plasma donors (boosted payment incentives no longer needed to attract donors as they were during COVID-19), the company ends this financial year in a strong position.
CSL’s earnings are heavily screwed to the first half of the year. Full Year NPAT is expected to be in the range of $2.15bn-$2.25bn.
CSL Daily Chart
The decline from the $342.75 high of February 2020 to the $240.10 low in February 2022 completed a correction and the CSL share price is eyeing trend channel resistance near $310/12 where profit taking/selling is likely to emerge.
Should the CSL share price break above the resistance at $310/12 and then above resistance at $320/21 it would likely open up a retest and break of the $342.75 high.
Source Tradingview. The figures stated are as of August 15, 2022. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation
- Open a Forex.com account, or log in if you’re already a customer.
- Search for the pair you want to trade in our award-winning platform.
- Choose your position and size, and your stop and limit levels.
- Place the trade.
Related tags:
Latest market news
View more newsOpen an account in minutes
Experience award-winning platforms with fast and secure execution.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.

Brazil Elections: Is Investor Confidence Beginning to Fade?
One of the most relevant events for emerging markets in recent sessions has been the outcome of Brazil’s presidential election. Following Lula da Silva’s victory in the second round, investor sentiment began to deteriorate noticeably. This can be observed in both the iShares MSCI Brazil ETF and the VanEck Brazil Small-Cap ETF, two important benchmarks for tracking the Brazilian equity market, both of which have posted declines of more than 15% at the start of the week.

ASX 200 Outlook: A Rates Trade Disguised as a Stock Market?
Australian bond futures have exhibited a far stronger relationship with the ASX 200 than Wall Street over recent months. Now both markets are displaying remarkably similar price structures.

Dow Jones Analysis: Is the DJIA Making a Comeback?
Recent trading sessions have become increasingly relevant for the Dow Jones, as the index has started to regain bullish momentum heading into the end of the week. Over the last three sessions, the DJIA has advanced by more than 0.6%, allowing buying pressure to regain prominence and raising the possibility of a more consistent short-term recovery.
StoneX Financial Ltd (trading as "FOREX.com") is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, FOREX.com does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date.
This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it. No opinion given in this material constitutes a recommendation by FOREX.com or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although FOREX.com is not specifically prevented from dealing before providing this material, FOREX.com does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. For further details see our full non-independent research disclaimer and quarterly summary.






